Sanofi (SNY) Gains from Investment Securities (2009 - 2026)

Sanofi has reported Gains from Investment Securities for 18 years, with the latest figure at -$83.7 million in Q2 2026.

• Quarterly Gains from Investment Securities fell 42.18% year-over-year to -$83.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$300.6 million (down 67.25% YoY) and the FY2025 annual result came in at -$409.7 million, down 4.77% from the prior year.
• Gains from Investment Securities slipped to -$83.7 million in Q2 2026 per SNY's latest filing, from $41.0 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $41.0 million in Q1 2026 and troughed at -$396.9 million in Q2 2022.
• A 5-year average of -$66.2 million and a median of -$14.0 million in 2023 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2022 and 2024: Gains from Investment Securities jumped 702.0% in 2022, then sank 2129.62% in 2024.
• Over 5 years, Gains from Investment Securities stood at $27.5 million in 2022, then sank by 463.25% to -$100.1 million in 2023, then decreased by 2.52% to -$102.6 million in 2024, then slipped by 18.01% to -$121.1 million in 2025, then surged by 30.87% to -$83.7 million in 2026.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered -$83.7 million, $41.0 million, and -$121.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.